A tyrosine kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Bemcentinib is an AXL receptor tyrosine kinase selective inhibitor. It has been investigated for its antineoplastic activity (NCIt).

Bemcentinib on DrugBank
Bemcentinib on PubChem
Bemcentinib on Wikipedia


R428; BGB324


Structure image - Bemcentinib


Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs
3CLpro Small molecule In silico
in silico 3.22

Predicted to inhibit the SARS-CoV-2 3C-like protease.

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Small molecule In vitro Screening
Huh7.5 cells; Calu-3 cells; primary normal human bronchial epithelial cells; iPSC-derived AT2 cells; SARS-CoV-2 strain USA WA1/2020 8.11

Inhibited SARS-CoV-2 replication in Huh7.5 cells and also in Calu-3 cells with an SI of >3.


AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04890509 A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients Completed Phase 2 Oct/20/2020 May/25/2021
  • Alternative id - BGBC020
  • Interventions - Drug: Bemcentinib|Other: SoC
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Nirmal Hospital Private Limited, Surat, Gujarat, India|Kasturba Medical College, Mangalore, Karnataka, India|JSS Hospital, Mysuru, Karnataka, India|Chopda Medicare & Research Centre Pvt. Ltd (CMARC) - Magnum Heart Institute, Nashik, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharastra, India|Krishna Institute of Medical Sciences (KIMS Hospitals), Secunderabad, Telangana, India|Maulana Azad Medical College, New Delhi, India|Worthwhile Clinical Trials, Lakeview Hospital, Mowbray, Benoni, South Africa|Tiervlei Trial Centre, Bellville, Cape Town, South Africa|Vergelegen Mediclinic, Somerset West, Cape Town, South Africa|Into Research, Groenkloof, Pretoria, South Africa|Clinical Projects Research, Worcester, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 115
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Sustained Clinical Improvement of at Least 2 Points (from randomization)|Percentage of Participants not Deteriorating According to the Ordinal Scale by 1, 2, or 3 Points|Duration of Oxygen Use|Number of Oxygen-free Days|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Duration of Ventilation|Number of Ventilation-free Days|Number of Participants with Any Form of New Ventilation Use|Duration of New Ventilation Use|Duration of Organ Support|Number of Participants with Response|Time to Live Discharge From the Hospital|Time From Treatment Start Date to Death|Overall Mortality|Change in the Ratio of Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2)|Number of Participants with Physical Examination Abnormalities|Number of Participants with Clinical Laboratory Abnormalities|Number of Participants with Vital Signs (blood pressure/heart rate/temperature/respiratory rate) Abnormalities|Number of Participants with Adverse Events (AEs)|Duration of Intensive Care Unit (ICU) and Hospitalization|National Early Warning Score 2 (NEWS2)|Time to NEWS2 of <=2, Maintained for at Least 24 Hours|Ranked Trajectory